Low SMC1A protein expression predicts poor survival in acute myeloid leukemia

Oncology Reports

Volumn 24, Issue 1, 2010, Pages 47-56

  Hömme, Claudia ^a   Krug, Utz ^a   Tidow, Nicola ^a   Schulte, Bernd ^a   Köhler, Gabriele ^a   Serve, Hubert ^b   Bürger, Horst ^c   Berdel, Wolfgang E ^a   Dugas, Martin ^a   Heinecke, Achim ^a   Büchner, Thomas ^a   Koschmieder, Steffen ^a   Müller Tidow, Carsten ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Institute of Pathology   (Germany)

Author keywords

Acute myeloid leukemia; Immunohistochemistry; Prognostic factor; SMC1A; Tissue microarray

Indexed keywords

CHROMOSOME PROTEIN; MESSENGER RNA; PRE MRNA PROCESSING FACTOR 4 HOMOLOG PROTEIN; RNA BINDING PROTEIN; STRUCTURAL MAINTENANCE OF CHROMOSOMES 1A PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; NONHISTONE PROTEIN; STRUCTURAL MAINTENANCE OF CHROMOSOME PROTEIN 1; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CANCER PATIENT; CANCER SURVIVAL; CELL LEVEL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENESCENCE; TISSUE MICROARRAY; UNINDEXED SEQUENCE; CLUSTER ANALYSIS; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; CLUSTER ANALYSIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77952994907     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000827     Document Type: Article

References (27)

1. Mrozek K, Heerema NA and Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18: 115-136, 2004.
2. Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008.
3. Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26: 4595-4602, 2008.
4. Marcucci G, Maharry K, Whitman SP, et al: High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25: 3337-3343, 2007. (Pubitemid 47325620)
5. Baldus CD, Tanner SM, Ruppert AS, et al: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 102: 1613-1618, 2003.
6. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B and Ganser A: High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108: 3898-3905, 2006. (Pubitemid 44864574)
7. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al: High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101: 837-845, 2003. (Pubitemid 36139348)
8. Campos L, Guyotat D, Archimbaud E, et al: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 79: 473-476, 1992.
9. List AF, Spier CS, Grogan TM, et al: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464-2469, 1996.
10. Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24: 3904-3911, 2006. (Pubitemid 46630738)
11. Schlenk RF, Benner A, Krauter J, et al: Individual patient databased meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22: 3741-3750, 2004. (Pubitemid 41102131)
12. Buchner T, Berdel WE, Schoch C, et al: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24: 2480-2489, 2006. (Pubitemid 46655599)
13. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323-3329, 1997. (Pubitemid 27229818)
14. Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94: 1086-1099, 1999.
15. Buchner T, Berdel WE, Haferlach C, et al: Older age is an independent risk factor in AML. Blood 112: A555, 2008.
16. Buchner T, Berdel WE, Haferlach C, et al: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27: 61-69, 2009.
17. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W and Haferlach T: The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 89: 1082-1090, 2004. (Pubitemid 39295479)
18. Wang Y, Barbacioru C, Hyland F, et al: Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 7: 59, 2006.
19. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998. (Pubitemid 28331029)
20. Montembault E, Dutertre S, Prigent C and Giet R: PRP4 is a spindle assembly checkpoint protein required for MPS1, MAD1, and MAD2 localization to the kinetochores. J Cell Biol 179: 601-609, 2007. (Pubitemid 350146247)
21. Vogt E, Kirsch-Volders M, Parry J and Eichenlaub-Ritter U: Spindle formation, chromosome segregation and the spindle checkpoint in mammalian oocytes and susceptibility to meiotic error. Mutat Res 651: 14-29, 2008.
22. Strunnikov AV and Jessberger R: Structural maintenance of chromosomes (SMC) proteins: conserved molecular properties for multiple biological functions. Eur J Biochem 263: 6-13, 1999.
23. Barber TD, McManus K, Yuen KW, et al: Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA 105: 3443-3448, 2008. (Pubitemid 351723572)
24. Narayan G, Bourdon V, Chaganti S, et al: Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 46: 373-384, 2007. (Pubitemid 46411328)
25. Hu G, Kim J, Xu Q, Leng Y, Orkin SH and Elledge SJ: A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev 23: 837-848, 2009.
26. Valk PJ, Verhaak RG, Beijen MA, et al: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628, 2004. (Pubitemid 38528701)
27. Bubendorf L, Nocito A, Moch H and Sauter G: Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195: 72-79, 2001.